Pfizer (PFE), Valneva Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Pfizer (PFE) PT Raised to $37 at Barclays

April 29, 2020 7:37 AM EDT

Barclays analyst Carter Gould raised the price target on Pfizer (NYSE: PFE) to $37.00 (from $36.00) while maintaining a Equalweight rating.... More

Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany

April 29, 2020 5:48 AM EDT

BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTechs Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a... More

Popular stocks with increasing unusual volume: ZM PFE F DAL CCL AAL NAT

April 29, 2020 4:31 AM EDT

Popular stocks with increasing unusual volume: ZM PFE F DAL CCL AAL NAT

... More

Pfizer (PFE) could begin U.S. testing for coronavirus vaccine soon - WSJ

April 28, 2020 1:14 PM EDT

Pfizer (NYSE: PFE) could begin U.S. testing for coronavirus vaccine soon - WSJ

... More

Pre-Open Movers 04/28: (IBIO) (RTIX) (FFIV) Higher; (NBES) (HLIT) (GAIA) Lower (more...)

April 28, 2020 9:27 AM EDT

Today's Pre-Open Stock Movers

iBio, Inc. (NYSE: IBIO) 50% HIGHER; provided an update on its COVID-19 vaccine manufacturing capacity and announced that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), one of 14 institutes in the Manufacturing USA Network.

RTI Surgical Holdings, Inc. (Nasdaq: RTIX) 29.9% HIGHER; announces a second amendment to its definitive agreement for the sale of RTI Surgical Holdings' OEM business to Montagu Private Equity LLP. Reduces the cash purchase price from $480,000,000 to... More

Merck sees $2.1 billion coronavirus hit to 2020 sales

April 28, 2020 7:08 AM EDT

By Manas Mishra

(Reuters) - Merck & Co Inc (NYSE: MRK) said on Tuesday it expects the coronavirus pandemic to reduce 2020 sales by more than $2 billion, and the U.S. drugmaker lowered its profit forecast as a big drop in doctors' office visits during the outbreak will take a hefty toll, sending its shares down more than 3%.

Many of Merck's top-selling products, including blockbuster cancer drug Keytruda, are administered by physicians.

Rival drugmakers Pfizer Inc (NYSE: PFE) on Tuesday stuck to its forecasts, and Eli... More

Pfizer (PFE) Tops Q1 EPS by 7c, Reaffirms FY20 EPS Guidance

April 28, 2020 6:47 AM EDT

Pfizer (NYSE: PFE) reported Q1 EPS of $0.80, $0.07 better than the analyst estimate of $0.73. Revenue for the quarter came in at $12 billion versus the consensus estimate of $11.89 billion.

GUIDANCE:

Pfizer sees FY2020 EPS of $2.82-$2.92, versus the consensus of $2.86. Pfizer sees FY2020 revenue of $48.5-50.5 billion, versus the consensus of $49.33 billion.

Todays guidance update reflects managements current expectations for operational performance, foreign exchange rates as well as various COVID-19-related uncertainties, primarily those related to the severity, duration and global macroeconomic impact of the pandemic. Key guidance assumptions related to... More